Capital Management I, Llc F... Net Worth

The estimated Net Worth of Capital Management I, Llc F... is at least $212 million dollars as of 12 May 2020. Capital F owns over 1,450,000 units of 10x Genomics stock worth over $51,935,000 and over the last 5 years Capital sold TXG stock worth over $160,438,500.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Capital F TXG stock SEC Form 4 insiders trading

Capital has made over 3 trades of the 10x Genomics stock since 2019, according to the Form 4 filled with the SEC. Most recently Capital sold 1,450,000 units of TXG stock worth $116,188,500 on 12 May 2020.

The largest trade Capital's ever made was selling 1,450,000 units of 10x Genomics stock on 12 May 2020 worth over $116,188,500. On average, Capital trades about 341,071 units every 35 days since 2019. As of 12 May 2020 Capital still owns at least 2,350,000 units of 10x Genomics stock.

You can see the complete history of Capital F stock trades at the bottom of the page.

Insiders trading at 10x Genomics

Over the last 5 years, insiders at 10x Genomics have traded over $629,686,183 worth of 10x Genomics stock and bought 487,816 units worth $19,025,295 . The most active insiders traders include Bryan E Roberts, Capital Management I, Llc F... et Benjamin J. Hindson. On average, 10x Genomics executives and independent directors trade stock every 8 days with the average trade being worth of $1,002,346. The most recent stock trade was executed by Serge Saxonov on 22 August 2024, trading 6,749 units of TXG stock currently worth $152,055.

What does 10x Genomics do?

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Complete history of Capital F stock trades at 10x Genomics

10x Genomics executives and stock owners

10x Genomics executives and other stock owners filed with the SEC include:

• Serge Saxonov,
  Chief Executive Officer, Co-Founder, Director
• Benjamin Hindson,
  President, Co-Founder, Chief Scientific Officer, Director
• Sridhar Kosaraju,
  Independent Director
• Shehnaaz Suliman,
  Independent Director
• Eric Whitaker,
  General Counsel
• Bryan Roberts,
  Independent Director
• Dr. Serge Saxonov Ph.D.,
  Co-Founder, CEO & Director
• Justin McAnear,
  Chief Financial Officer
• Dr. Benjamin J. Hindson Ph.D.,
  Co-Founder, Pres, Chief Scientific Officer & Director
• Bradford J. Crutchfield,
  Chief Commercial Officer
• Ruth De Backer,
  Chief Bus. Officer
• Justin J. McAnear,
  Chief Financial Officer
• John Stuelpnagel,
  Independent Chairman of the Board
• Mathai Mammen,
  Independent Director
• Kimberly Popovits,
  Independent Director
• Bradford Crutchfield,
  Chief Commercial Officer
• Jean Philibert,
  Chief People Officer
• Sam Ropp,
  Sr. VP of Global Sales
• Jonathan Schimmel,
  VP of Global Support & Sales Operations
• Eric S. Whitaker,
  Gen. Counsel
• Cassie Corneau,
  Mang. of Investor Relations and Strategic Fin.
• Paul W. Wyatt,
  Sr. VP of Operations
• Capital Management, Llc Pal...,
  
• Associates Vi, L.P.Venrock ...,
  
• Vision Fund (Aiv M2) L.P.Sb...,
  
• Capital Management I, Llc F...,
  
• Sarah A. Teichmann,
  
• James Wilbur,
  Chief Commercial Officer
• Alan Mateo,